RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase

被引:103
作者
Badea, T
Niculescu, F
Soane, L
Fosbrink, M
Sorana, H
Rus, V
Shin, ML
Rus, H
机构
[1] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Div Clin Immunol & Rheumatol, Baltimore, MD 21201 USA
关键词
D O I
10.1074/jbc.M109354200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proliferation of aortic smooth muscle cells contributes to atherogenesis and neointima formation. Sublytic activation of complement, particularly C5b-9, induces cell cycle progression in aortic smooth muscle cells. RGC-32 is a novel protein that may promote cell cycle progression in response to complement activation. We cloned human RGC-32 cDNA from a human fetal brain cDNA library. The human RGC-32 cDNA encodes a 117-amino acid protein with 92% similarity to the rat and mouse protein. Human RGC-32 maps to chromosome 13 and is expressed in most tissues. Sublytic complement activation enhanced RGC-32 mRNA expression in human aortic smooth muscle cells and induced nuclear translocation of the protein. RGC-32 was physically associated with cyclin-dependent kinase p34(CDC2) and increased the kinase activity in vivo and in vitro. In addition, RGC-32 was phosphorylated by p34(CDC2)-cyclin B1 in vitro. Mutation of RGC-32 protein at Thr-91 prevented the p34(CDC2)-mediated phosphorylation and resulted in loss of p34(CDC2) kinase enhancing activity. Overexpression of RGC-32 induced quiescent aortic smooth muscle cells to enter S-phase. These data indicate that cell cycle activation by C5b-9 may involve p34(CDC2) activity through RGC-32. RGC-32 appears to be a cell cycle regulatory factor that mediates cell proliferation, both as an activator and substrate of p34(CDC2).
引用
收藏
页码:502 / 508
页数:7
相关论文
共 39 条
[11]  
IMAGAWA DK, 1986, J IMMUNOL, V136, P4637
[12]  
KITAGAWA M, 1994, ONCOGENE, V9, P2549
[13]   Neointimal tissue response at sites of coronary stenting in humans - Macroscopic, histological, and immunohistochemical analyses [J].
Komatsu, R ;
Ueda, M ;
Naruko, T ;
Kojima, A ;
Becker, AE .
CIRCULATION, 1998, 98 (03) :224-233
[14]   CYTOLYSIS OF NUCLEATED CELLS BY COMPLEMENT - CELL-DEATH DISPLAYS MULTI-HIT CHARACTERISTICS [J].
KOSKI, CL ;
RAMM, LE ;
HAMMER, CH ;
MAYER, MM ;
SHIN, ML .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (12) :3816-3820
[15]  
Lang TJ, 1997, J NEUROCHEM, V68, P1581
[16]  
LIANG P, 1997, DIFFERENTIAL DISPLAY, P3
[17]  
LOYER P, 1994, J BIOL CHEM, V269, P2491
[18]   ACTIVATION OF THE P34 CDC2 PROTEIN-KINASE AT THE START OF S-PHASE IN THE HUMAN CELL-CYCLE [J].
MARRACCINO, RL ;
FIRPO, EJ ;
ROBERTS, JM .
MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (04) :389-401
[19]   Human Cdc7-related kinase complex -: In vitro phosphorylation of MCM by concerted actions of Cdks and Cdc7 and that of a critical threonine residue of Cdc7 by Cdks [J].
Masai, H ;
Matsui, E ;
You, ZY ;
Ishimi, Y ;
Tamai, K ;
Arai, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (37) :29042-29052